GlassScriptPhysician profile
Krishna L Schmidt
NPI 1013075464
$18,189.81
in general payments reported to CMS, 2019-2025
34 companies · $2,878 in 2025
The $2,878 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,793 · 2022: $3,746 · 2023: $4,170 · 2024: $4,603 · 2025: $2,878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $850 · Education: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,512.57 |
| Consulting Fee | $850.00 |
| Education | $288.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,158.58 | 2021-2025 | |
| Janssen Biotech, INC. | $2,671.62 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $1,570.41 | 2021-2025 | Winlevi, Blu-U, Ilumya |
| Lilly USA, LLC | $1,088.54 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $882.11 | 2021-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $865.77 | 2021-2025 | |
| Ucb, INC. | $817.36 | 2021-2025 | Bimzelx, Cimzia |
| Mayne Pharma Commercial LLC | $809.56 | 2021-2025 | |
| Amgen INC. | $802.73 | 2021-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $693.01 | 2022-2025 | Sotyktu |
| Almirall LLC | $679.25 | 2021-2025 | Seysara |
| Dermavant Sciences, INC. | $621.96 | 2023-2024 | Vtama |
| Pfizer INC. | $570.51 | 2021-2024 | |
| Genzyme Corporation | $517.29 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $431.06 | 2021-2025 | Arazlo, Cabtreo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $411.87 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $407.17 | 2021-2024 | Dupixent |
| Paratek Pharmaceuticals, INC. | $278.51 | 2022-2025 | Nuzyra |
| Journey Medical Corporation | $123.65 | 2021 | |
| Galderma Laboratories, L.P. | $113.92 | 2022-2025 | Aklief, Nemluvio |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 | |
| Allergan, INC. | $89.59 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.66 | 2022-2024 | Cyltezo, Spevigo |
| Kyowa Kirin, INC. | $61.89 | 2022 | |
| Janssen Pharmaceuticals, INC | $51.54 | 2024 | Tremfya |
| Arcutis Biotherapeutics, INC. | $46.58 | 2023-2024 | Zoryve |
| Sandoz INC. | $44.76 | 2021 | |
| Dermira, INC. | $42.72 | 2021 | |
| Organon LLC | $40.08 | 2025 | Hadlima |
| Vyne Pharmaceuticals INC. | $35.07 | 2021 | |
| Nabriva Therapeutics, Plc | $25.60 | 2021-2022 | |
| Stemline Therapeutics INC. | $23.08 | 2021 | |
| Genentech USA, INC. | $20.85 | 2025 | Xolair |
| Helsinn Therapeutics (U.S.), INC. | $14.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishna Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.